Amyloid plaques contain many proteins in addition to beta amyloid (Aβ). Previous studies
examining plaque-associated proteins have shown these additional proteins are important; …

Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for
various cerebral proteopathies. Here we leverage the unique characteristics of the …

Biomarkers to assist in the diagnosis and medical management of Alzheimer disease (AD)
are a pressing need. We have employed a proteomic approach, microcapillary liquid …

Tau pathology in Alzheimer's disease (AD) spreads in a predictable pattern that corresponds
with disease symptoms and severity. At post-mortem there are cortical regions that range …

A biomarker of synapse loss, an early event in Alzheimer's disease (AD) pathophysiology
that precedes neuronal death and symptom onset, would be a much-needed prognostic …

Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease
mechanisms and alterations of biomarkers during the development of AD. Using cross …

Cerebrospinal fluid (CSF) biomarkers based on the core pathological proteins associated
with Alzheimer's disease (AD), ie, amyloid-β (Aβ) and tau protein, are widely regarded as …

Although complex inflammatory-like alterations are observed around the amyloid plaques of
Alzheimer's disease (AD), little is known about the molecular changes and cellular …